YOLFTbeta
Jia Jie Biomedical Co Ltd

Jia Jie Biomedical Co Ltd

4109 · TWO · Consumer Defensive / Packaged Foods

10.30TWD+0.10 (+0.98%)

Price History

Full chart

Market Stats

Previous Close10.20
Open10.10
Day Range10.10 – 10.30
52-Week Range10.16 – 16.60
Volume62.15K
Market Cap1.31B
P/E (TTM)366.67
Forward P/E0.00
EPS0.03
Dividend Yield1.82%
Beta-0.04
50-Day Avg11.16
200-Day Avg12.46

About

Jia Jie Biomedical Co., Ltd. produces and sells health foods in Taiwan and Mainland China. It operates through two segments: Nutritional Health Products and Insurance Brokerage. The company engages in the processing, sale, and trading of softshell turtle food; manufacture of dairy products; miscellaneous food manufacturing, such as softshell turtle egg powder capsules, enzyme powder, tortoise jelly, softshell turtle oil, and powder capsules; and import and export, distribution, bidding, quotation of the products. It also involved in the wholesale of nonalcoholic beverages, candy, baked food, supplementary food, groceries, daily commodities, and cosmetics; production of water purification equipment and related parts; life and property insurance brokerage business; development and production of aquatic product technology; and development of biological products. The company was formerly known as Murad Chia Jei Biotechnology Co., Ltd. and changed its name to Jia Jie Biomedical Co., Ltd. in June 2019. Jia Jie Biomedical Co., Ltd. was founded in 1995 and is based in Kaohsiung, Taiwan.

Company Details

  • SectorConsumer Defensive
  • IndustryPackaged Foods
  • CEOWen-Fang Hsieh
  • Employees0
  • HeadquartersNo. 61, Jiuru 1st Road, Kaohsiung, Taiwan, 807, Taiwan
  • Websitehttps://www.jiajiebio.com

Leadership

  • Wen-Fang HsiehChief Executive Officer
  • Ming-Chuan TsengPresident
  • Qinghong LinVP of Finance Department & Accounting supervisor

Financials

Income Statement

Currency: TWD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue797.49M626.06M521.75M402.03M343.06M270.29M242.48M317.72M332.76M537.07M485.40M
Growth (%)--21.50%-16.66%-22.95%-14.67%-21.21%-10.29%+31.03%+4.73%+61.40%-9.62%
Cost of Revenue500.14M403.07M389.98M292.20M255.10M228.58M158.71M201.21M215.12M363.72M335.07M
Gross Profit297.34M222.98M131.78M109.83M87.97M41.71M83.77M116.51M117.64M173.35M150.34M
Gross Margin37.28%35.62%25.26%27.32%25.64%15.43%34.55%36.67%35.35%32.28%30.97%
Operating Expense199.54M185.21M191.02M153.49M112.41M90.03M85.00M130.90M184.12M140.13M149.64M
Operating Income97.80M37.77M-59.24M-43.67M-24.44M-48.32M-1.23M-14.39M-66.48M33.22M696.00K
Operating Margin12.26%6.03%-11.35%-10.86%-7.12%-17.88%-0.51%-4.53%-19.98%6.19%0.14%
EBITDA---211.82M27.60M-4.22M-25.28M18.79M12.30M161.78M241.93M77.67M
EBITDA Margin---40.60%6.86%-1.23%-9.35%7.75%3.87%48.62%45.05%16.00%
Net Income37.84M11.63M-232.09M2.47M-24.48M-31.93M5.34M-5.47M144.15M211.37M50.26M
Net Income Margin4.74%1.86%-44.48%0.62%-7.14%-11.81%2.20%-1.72%43.32%39.36%10.35%
R&D30.97M11.50M3.27M2.13M1.92M165.00K3.61M8.94M9.32M6.55M6.74M
R&D as % of Total Revenue3.88%1.84%0.63%0.53%0.56%0.06%1.49%2.81%2.80%1.22%1.39%
Interest Expense0009.09M2.90M713.00K61.00K113.00K348.00K641.00K277.00K
Interest Expense % of Total Revenue0.00%0.00%0.00%2.26%0.85%0.26%0.03%0.04%0.10%0.12%0.06%

Balance Sheet

Currency: TWD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.58B1.65B1.32B1.12B855.81M989.41M1.02B1.00B1.41B1.48B1.89B
Total Liabilities595.84M684.91M621.58M404.40M160.92M81.44M86.47M80.00M342.69M123.08M174.89M
Total Equity951.25M935.13M690.01M707.65M695.41M909.28M907.88M897.98M1.05B1.33B1.68B
Cash204.32M155.25M137.72M154.82M104.38M344.16M172.28M125.53M354.42M112.94M296.47M
Net Debt--370.07M144.19M-------

Cash Flow

Currency: TWD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow82.22M-76.54M-13.73M-13.10M24.71M27.10M4.37M-8.78M-4.49M44.35M21.34M
Investing Cash Flow-271.35M-91.69M78.80M227.09M186.98M7.33M-173.05M----
Financing Cash Flow218.95M133.07M-74.43M-194.33M-258.93M205.75M-2.48M-3.73M234.57M--
Capital Expenditure273.85M32.06M3.49M8.34M3.05M1.63M1.52M17.86M8.61M19.63M85.50M
Free Cash Flow---1.46M-5.66M21.66M25.47M2.85M-26.64M-13.10M24.72M-64.15M
Dividends Paid14.33M14.88M6.25M------49.37M59.37M
FCF to OCF--10.60%43.25%87.64%93.97%65.26%303.45%291.89%55.74%-300.59%
Dividend Paid to FCF---429.48%------199.71%-92.54%

Earnings

Report DateFeb 4, 2009
EPS Estimate-
EPS Actual0.01
Surprise-
TimingPre-market

Key Statistics & Ratios

Market Cap1.31B
Enterprise Value904.24M
Trailing P/E366.67
Forward P/E0.00
Price / Sales2.54
Price / Book0.81
EPS0.03
Book Value13.69
Revenue (TTM)514.65M
Gross Profit (TTM)138.70M
EBITDA5.95M
Profit Margin0.60%
Operating Margin-0.21%
Return on Equity0.22%
Return on Assets-0.39%
Shares Outstanding118.74M
Shares Float91.55M
Beta-0.04
Dividend Yield1.82%
Dividend Rate0.20
Payout Ratio1526.25%

Dividends

20251×
0.50Sep 24, 2025
20241×
0.49Aug 26, 2024
20171×
0.09Sep 5, 2017
20161×
0.21Sep 12, 2016
20151×
0.21Sep 14, 2015
20141×
0.28Sep 24, 2014
20131×
0.39Sep 24, 2013
20101×
0.40Sep 13, 2010
20091×
0.39Sep 14, 2009
20081×
0.60Sep 4, 2008

Stock Splits

  • Mar 21, 2019848.7829:1000
  • Sep 5, 20171040:1000
  • Sep 12, 20161050:1000
  • Sep 14, 20151040.281:1000
  • Sep 24, 20141038.531:1000
  • Sep 24, 20131.0398:1
  • Sep 24, 20121.08:1
  • Sep 23, 20111.0593:1
  • Sep 13, 20101030:1000
  • Sep 14, 2009102:100
  • Sep 4, 2008103:100